Adiponectin is a well-known insulin sensitizer and anti-inflammatory molecule, possessing therapeutic potentials in cardiovascular, metabolic and cancer diseases. Results of the present study demonstrate that adiponectin is expressed in a population of regulatory T-cells (Treg) resided within the thymic nurse cell (TNC) complexes. Adoptive transfer of adiponectin-expressing Treg precursors effectively attenuated obesity, improved glucose and insulin tolerance, prevented fatty liver injuries in wild-type mice fed a high-fat diet, and significantly inhibited breast cancer development in MMTV-PyVT transgenic mice. Within the TNC complexes, locally produced adiponectin bound to and regulated the expression as well as the distribution of CD100, a transmembrane lymphocyte semaphorin, in turn modulating the lymphoepithelial interactions to facilitate T-cell development and maturation. In summary, adiponectin plays an important role in the selection and development of T lymphocytes within the TNC complexes. Adiponectin-expressing Treg represent a promising candidate for adoptive cell immunotherapy against obesity-related metabolic and cancer diseases.
Keyphrases
- insulin resistance
- metabolic syndrome
- high fat diet
- cell therapy
- high fat diet induced
- type diabetes
- regulatory t cells
- wild type
- adipose tissue
- single cell
- skeletal muscle
- primary care
- glycemic control
- anti inflammatory
- papillary thyroid
- stem cells
- weight loss
- young adults
- dendritic cells
- transcription factor
- blood pressure
- body mass index
- immune response
- long non coding rna
- fluorescent probe
- squamous cell
- nk cells